profit from every $100 of sales.
$0$100
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
$442.19-3.75% today
+31.9% in 1 year
1-year low $264.671-year high $484.21
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A sold, what it kept, and what it did with the cash.
Sales went from $2.53 billion in 2022 to $3.44 billion in 2025, with -$8.60 million of profit last year.
SalesProfit
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A handed back more cash to shareholders than it generated last year.
$33M
Free cash flow 2025$14M
Bought back its own shares$10M
Paid as dividends$33M
Cash vs. debt$299M vs. $2.0B
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | No profit yet | ||
 Boston Scientific | 22.1× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.5× · Expensive | ||
 Zimmer Biomet Holdings | 28.1× · Fair price |
AI analysis
An AI analyst reads Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,531 | 2,965 | 3,366 | 3,437 | |
| 1,306 | 1,513 | 1,650 | 1,578 | |
| 462 | 489 | 379 | 236 | |
| 519 | 676 | 439 | 303 | |
| 297 | 427 | 113 | -9 | |
| – | – | – | – | |
| 51.6% | 51.0% | 49.0% | 45.9% | |
| 18.3% | 16.5% | 11.3% | 6.9% | |
| 11.7% | 14.4% | 3.4% | -0.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,612 | 4,250 | 5,807 | 6,241 |
| Cash | 646 | 488 | 183 | 299 |
| Total debt | 1,270 | 1,380 | 2,245 | 2,043 |
| Total liabilities | 2,480 | 2,837 | 3,992 | 3,731 |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 274 | 350 | 251 | 134 | |
| 129 | 107 | 115 | 120 | |
| 145 | 243 | 136 | 14 | |
| Dividends paid | 30 | 29 | 30 | 33 |
| 263 | 152 | 0 | 10 | |
| 28 | 31 | 25 | 20 |
Valuation
- –
- –
- 5.46
- 2.8×
- 1.7×
- 132.9×
- 25.2×
- 0.1%
- -0.1%
- 0.4%
Profitability
- 45.9%
- 6.9%
- -0.3%
- 8.6%
- -2.9%
- 8.4%
- -0.4%
- -0.1%
- 3.8%
- 11.5%
Growth
- +10.7%
- –
- −68.2%
- –
- +0.1%
Financial health
- 4.8×
- 0.68
- 32.7%
- 3.3×
- 1.55
- 0.87
- 0.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 32%of 952
Bottom 44%of 883
Bottom 48%of 870
Bottom 40%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.31 | 0.23 | +35.1% |
| Feb 12, 2026 | 0.59 | 0.65 | −9.2% |
| Nov 3, 2025 | -0.39 | 0.35 | −211.0% |
0.4%of the share price, paid each year
On $1,000 invested$4a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
-377.6% of its profit
Room to growStretchedMore than it earns: 236.7%
News
Bruker expects FY 2026 non-GAAP EPS of $2.10-$2.15 while targeting 250-300 bps operating margin expansionSeeking Alpha · Nov 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
27No pass
Philip Fisher
36No pass
Peter Lynch
46No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
30No pass
Questions about Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Is Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A AI analysis
What does Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A do?
Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It is in Medical - Devices.
Does Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A pay a dividend?
Yes. At today's price the dividend is 0.4% a year. In 2025 it paid out $32.9 million in dividends.
How has Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A stock done over the past year?
Up 31.9% over the past twelve months, to $442.19. It traded between $264.67 and $484.21 and is 8.7% below its high.
Who are Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.